Wednesday, 24 October 2018

Current and forthcoming Magnetic Resonance Imaging (MRI) Market size in terms of volume and value 2018

Market Scenario
The global Magnetic Resonance Imaging (MRI) Systems market is expected to be of value USD 5 Billion in 2023 and to grow at a depict 3.5% CAGR during the forecast period.  Magnetic resonance imaging (MRI) systems is a non-invasive technique in which light is used to interrogate cellular and molecular function in the living body by exploiting the special properties of photons. Magnetic resonance imaging (MRI) systems are surpassing the radiology imaging market due to its myriad advantages over it. This market is mainly driven by rising demand for non-invasive procedures, harmful effects of radiation-based imaging, increase in research and development activities in the life sciences sector, and increasing application of magnetic resonance imaging (MRI) systems techniques in drug discovery processes and preclinical research, Moreover factors such as rising geriatric population which leads to increase in cardiovascular, neurological and ophthalmic disorders is also fueling the growth of this market. However, the market growth is restricted by factors such as stringent regulatory approval procedures high costs of instruments, scarcity of skilled operators, and insufficient reimbursements policies for magnetic resonance imaging (MRI) systems procedures.
Market Segmentation                                                                                                                          
The global magnetic resonance imaging (MRI) systems market is segmented on the basis of type, field strength, disease application and end user.
Considering the type, the market is segmented into open MRI, closed MRI, standard bore MRI, wide-bore MRI.
On the basis of field strength, the market is segmented into high-field MRI systems, 1.5t MRI systems, 3t MRI systems, low-to-mid-field MRI systems, very-high-field MRI systems, and others.
On account of disease application, the market is segmented into the spine and musculoskeletal MRI, brain and neurological MRI, pelvic and abdominal MRI, breast MRI, cardiovascular MRI, and others
According to the end user, the market is segmented into diagnostic imaging centers, hospitals and clinics, research laboratories, and pharmaceutical &biotechnology companies.
Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Market Players
  • Hitachi
  • Siemens AG
  • Canon Medical Systems
  • GE Healthcare
  • Philips
  • Toshiba Corporation
  • Toshiba Corporation
  • Xingaoyi
  • Aurora Imaging Technologies, Inc.
Regional Market Summary
In terms of geography, Americas dominates the market for Magnetic Resonance Imaging (MRI) systems owing to increasing prevalence of cardiovascular, neurological and ophthalmic disorders pertaining to rising geriatric population which is a major trigger factor for this disease. Additionally, factors such as increasing government initiatives and funding for research in the medical devices sector, rising demand for accurate diagnosis, awareness about adverse effects of radiation imaging, ability to provide in-depth images of soft tissues and vascular systems, and the presence of pharmaceutical giants also propel the market growth in this region. For instance, according to National Center for Health Statistics report in 2016, around 140,323 mortality occurred due to cerebrovascular disease or stroke in the US Thus, this rising patient pool is going to boost up the market growth during the forecast period.
Europe accounts for the second largest market and holds a healthy share in the global magnetic resonance Imaging (MRI) systems market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure, good healthcare infrastructure and flourishing medical device industry due to the presence of major market players. Additionally, knowledge about the benefits of Magnetic Resonance Imaging (MRI) Systems over radiation imaging and capability of inhabitants to afford the diagnostics is spurring the market growth.
Asia Pacific is expected to be the fastest growing market with most promising growth possibilities. According to a report published by the Department of Neurology in 2014, it is estimated that for the current population of 1.27 billion, approximately 30 million people suffer from neurological disorders in India. Thus, owing to the huge patient pool, a faster adaptation of healthcare technology, government initiatives to increase the healthcare quality, availability favorable insurance policies market growth will be accelerated during the forecast period.  Moreover, due to lower cost of clinical trials and research key players have been setting up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia which make a positive growth curve in  Magnetic Resonance Imaging (MRI) Systems market in future.
 The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates and Saudi Arabia is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. Hence, the market might show steady growth due to Saudi Arabia, the UAE market growth, and government initiatives to improve quality of healthcare in the Africa region.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Cell Isolation Market 2018 Market Challenge, Driver, Trends & Forecast to 2023

Market Scenario
Cell isolation is viewed as a highly sophisticated process, which has tremendous potential. It is currently used for understanding how cells function. Physicians are also employing cell isolation to find out how cells respond to different diseases and how they are affected by different drugs. In 2017, the global market for cell isolation stood at USD 4, 098.5 Mn and is likely to surpass a valuation of USD 10,500 Mn by the years 2023. While cell isolation is already being considered for treatment purposes, its application is likely to proliferate to various other fields of healthcare science in the future. Cell culture, a process of multiplication of cells to create a cell colony also involves cell isolation.  Other factors that are anticipated to support the growth of the cell isolation market include rising cancer prevalence, increased government funding for cell-based research and advances in cell analysis techniques.
Report Overview
This MRFR market perspective delivers an exhaustive assessment of the current trends in cell isolation process and its market opportunities. It also includes a discussion on the key market dynamics such as drivers and critical restraints that are influencing or disrupting the cell isolation market landscape. A revenue analysis on various sub-markets is also available in research document, which will enable investors to identify revenue pockets that are likely to remain highly lucrative throughout the review period. Major types of product used for cell isolation process covered in the report include consumables and instruments. The overall market sizing based on cell types covers human cells and animal cells. Centrifugation-based cell isolation, surface marker-based cell isolation and filtration-based cell isolation are the major techniques profiled in the report. The currently application areas identified include biomolecule isolation, cancer research, stem cell research, tissue regeneration, in vitro diagnostics and therapeutics. A revenue analysis based on primary end-users (research laboratories and institutes, biotechnology and biopharmaceutical companies, hospitals and diagnostic laboratories, and cell banks) is also available.
Report Coverage
Value, Market Share, Player Analysis, supply chain analysis, Porter's five forces model, demand & supply: gap analysis, investment opportunities analysis, pricing analysis, country level break down for product, cell type, technique, application, end-user.
Players Covered
Thermo Fisher Scientific Inc., GE Healthcare, Becton, Dickinson and Company, Beckman Coulter, Merck KGaA, STEMCELL Technologies, Miltenyi Biotec, TERUMO CORPORATION, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG.
Research Methodology
Market Research Future (MRFR) makes comparative assessment of all the market parameters on multiple levels to deliver a macro overview. The projections are made after an in-depth study of various elements such as historical market trends, key developments, and, shifts in consumer behavior. Robust scientific methods are employed for ascertaining the statistical observations. The fail-safe interpretation of data is backed by credible inputs sourced through primary and secondary research which includes interviews with stakeholder across the value chain (CEOs, Business Development Managers, Vice Presidents, etc.), white paper references, research publications, and, reports published by national and international organizations among others. A multi-layer verification process authenticates market forecast and ensures cross-verification of information delivered. Top-down and bottom-up approaches are employed to validate the accuracy of the market size and revenue estimation. MRFR uses innovative and sound analytical algorithms for ensuring the optimum quality of research findings.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Conjugate Vaccine Market 2018 - Opportunity, Driving Trends and deep study 2023


Market Scenario

Conjugate Vaccines are formed by covalently bonding a weak antigen to the strong antigen. This is done to boost the hosts’ immunological response. The poor antigen is a polysaccharide that is attached to the strong protein antigen. The major drivers for the growth of the global conjugate vaccine market are initiatives taken by the government, advancement in the vaccine formulation, and prevention of major infectious diseases, for instance meningitis and others. Furthermore, increasing investments by the companies in research & development, rising focus on immunization programs, and growing demand for vaccination expected to boost the growth of the market over the review period. Increasing prevalence of infectious diseases in children and rising number of awareness programs to promote vaccination will drive the growth of this market during the forecast period.
The strength or effectiveness of conjugate vaccines needs to improve, which may hamper the growth of the market.
The global conjugate vaccine market is expected to grow at a healthy CAGR of 10.5% during the forecast period 2017-2023.
Intended Audience
  • Research and development (R&D) companies
  • Government and independent research laboratories
  • Government and independent regulatory authorities
  • Academic medical institutes and universities
  • Pharmaceutical industries
Segments                                                                                                                                            
The global Conjugate vaccine is segmented on the basis of type, indication, and end users. On the basis type it is segmented into Haemophilus B, monovalent, multivalent, others. On the basis of indication, it is segmented into Influenza, Pneumococcal, Meningococcal, others. On the basis of end users, it is segmented into pediatrics and adults.
Regional Analysis of the Global Conjugate vaccines Market    
On the regional basis, the market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. America dominates the largest market due to a significant use of the vaccine for preventing diseases and favorable conditions for research and development.
Europe is the second largest Conjugate Vaccines market in the globe followed by Asia Pacific. In Europe availability of funds for research and development activities and growing emphasis on research for prevention measures of diseases is increasing. Whereas, Asia Pacific shows the fastest growth in this market due to the increasing prevalence of communicable diseases. Developing countries in this region are emphasizing research on diseases caused to children’s and preventive measures for treating them. Mainly, India and China are expected to be an emerging and the fastest growing market due to the increasing population and prevalence of diseases.
The Middle East & Africa owns the lowest market in the global conjugate vaccines market due to less availability medical facilities.
Key Players in the Global Conjugate vaccines Market                                          
Some of the key players in this market are GlaxoSmithKline plc. Merck & Co., Inc. (U.S), Fablife. (India), SutroVax Inc.(U.S), Sanofi Pasteur SA.(France), Pfizer (U.S), Sinovac Biotech Ltd. (China), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(U.S).
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: , , , , , ,

Cell Therapy Market 2018 Global Trend, Segmentation and Opportunities Forecast To 2023

Market Scenario
Cell therapy has come forward as a recent phase of the biotechnology revolution in medical sector. As cell therapy is based on ground-breaking scientific discoveries and various technological advancements. The main aim of cell therapy is to target various diseases at the cellular level by restoring a certain cell population as carriers of therapeutic cargo. It is also used in combination with gene therapy for many diseases. For many diseases, gene and cell therapy are applied in combination.
With new technologies, and different types of cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, skeletal muscle stem cells, lymphocytes, pancreatic islet cells, and dendritic cells, cell therapy can be used for the treatment of a variety of diseases. Hematopoietic stem cell transplantation or Bone marrow transplant is the most commonly used cell therapy to treat a variety of hematologic conditions and blood cancers. Potential applications of cell therapy include treatment of cancers, urinary problems, autoimmune disease, and infectious disease, repairing spinal cord injuries, rebuilding damaged cartilage in joints, improving the immune system, and treatment of neurological disorders.
Adipose tissue-derived stem cells (ADSCs) are another most promising cell types for application in regenerative therapies. Regenerative medicine is an interdisciplinary field comprises of tissue engineering, with an objective of restoration or establishment of the normal functioning of organs.
Around the world stem cell therapy, and related products are being regulated by various guidelines and laws based on the regulatory agencies in charge, i.e. the Food and Drug Administration (FDA) in the USA, the European Medicines Agency (EMA) in Europe, different and other regional authorities. According to a study published in Transfusion Medicine and Hemotherapy in 2016, it is found that the therapeutic products based on gene therapy, and somatic cell therapy are defined as advanced therapy medicinal products (ATMP), in Europe.
Notably, rising prevalence of chronic disorders is the key factor driving the cell therapy market. According to a study published in Neurology India journal in 2014, it is found that out of total population of India, around 30 million people were suffering from neurological disorders.
Various other push factors such as increasing geriatric population, increasing government assistance, replacement of animal testing model, technological advancements, and improvement in regulatory framework continuously contribute to the growth of the global cell therapy market. As per the instructions suggested by the FDA on the regulation of tissue engineering, the purity and quality of engineered tissue should be maintained and regulated to avoid any kind of chemical instability.
Despite these drivers, there are some issues associated with cell therapy market. Challenges in research and development, the high cost of manufacturing, and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.
It is estimated that cell therapy market is expected to grow at a CAGR 10.6% during the forecast period of 2017-2023.
Segmentation
The cell therapy market is segmented on the basis of type, technology, cell source, application, and end-user.
On the basis of type, the market is segmented into autologous, and allogeneic.
On the basis of technology, the market is classified into somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and three-dimensional technology. Viral vector technology is further segmented into Ex vivo gene modification of cells and In vivo gene modification of cells.
On the basis of cell source, the market is classified into induced pluripotent stem cells (iPSCs), bone marrow, umbilical cord blood-derived cells, adipose tissue, and neural stem cell.
On the basis of application, the market is classified into musculoskeletal, cardiovascular, gastrointestinal, neurological, oncology, dermatology, wounds and injuries, ocular, and others.
On the basis of end-users, the market is segmented into hospital & clinics, regenerative medicine centers, diagnostic centers, research institutes, and others.
Regional Analysis
The Americas dominate the cell therapy market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in cell therapy market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
The Asia Pacific is the fastest growing cell therapy market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014–15.
The Middle East & Africa has the lowest market for cell therapy due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the cell therapy market are Novartis AG, GlaxoSmithKline plc, MEDIPOST, Osiris, PHARMICELL, NuVasive, Inc., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO.,LTD., Cynata, CELLECTIS, BioNTech IMFS, EUFETS GmbH, Cognate, Pluristem, Grupo Praxis, Genzyme Corporation, Advanced Tissue and others. 
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Labels: , , , ,

Appendiceal Cancer Treatment Market Growth and Restrain Factors Analysis By 2023

Market Scenario
The appendix is a tube-like structure, which is three to six inches long and is attached to the colon. It is situated in the lower right part of the abdomen. Appendiceal cancer or the cancer of the appendix is mostly found after the patients have surgery for acute appendicitis or when an abdominal mass is seen on a computerized tomography scan. The global appendiceal cancer treatment market is expected to grow significantly over the forecast period.
Several factors such as a rise in targeted and innovative therapies confined to appendiceal cancer and increased awareness about the severity of the disease are anticipated to drive the growth of the market. According to the American Society of Clinical Oncology (ASCO), acute appendicitis is the most common cause in the US for an attack of severe, acute abdominal pain that requires an abdominal operation.
Additionally, in January 2018, GE Healthcare announced that it has entered into a long-term, strategic partnership with Roche Diagnostics to co-develop and market digital clinical decision support solutions. With this, the companies will initially focus on products that accelerate and improve individualized treatment options for cancer and critical care patients.
Appendix cancer usually does not cause symptoms until it is in an advanced stage and has spread to other parts of the body. Therefore, it becomes difficult to diagnose it in the right stage where corrective action can be taken. However, stringent government regulations about product approvals may hamper the market growth during the assessment period.
Segmentation
The global appendiceal cancer treatment market has been segmented into type, treatment, and end-user.
The market, on the basis of type, has been segmented into neuroendocrine tumors and carcinomas.
The market, based on carcinomas, has been sub-segmented into mucinous adenocarcinoma, goblet cell carcinoids, intestinal-type adenocarcinoma, signet-ring cell adenocarcinoma, and paraganglioma.
The market, by treatment, has been segmented into surgery, chemotherapy, and radiation therapy.
The market, based on surgery, has been further segmented into appendectomy, hemicolectomy, and cytoreduction.
The market, based on chemotherapy, has been sub-segmented into hyperthermic intraperitoneal chemotherapy and systemic chemotherapy. The hyperthermic intraperitoneal chemotherapy segment is expected to be the largest segment due to its specificity to treat appendiceal cancer and also the high efficacy of drugs, whereas systemic chemotherapy is expected to be the fastest growing segment. This rapid growth is due to increasing awareness about the chemotherapeutic treatment and its increasing adoption rate by patients.
The market, by end-user, has been segmented into hospitals and clinics, cancer research institutes, and others.
Key players
AbbVie, Inc., Pfizer Inc., Eli Lilly & Company, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd., Becton, Dickinson & Company, Novartis AG, General Electric Company, AstraZeneca, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Sanofi, Bayer AG, Amgen Inc., and Merck are some of the key players in the global appendiceal cancer treatment market.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The appendiceal cancer treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European appendiceal cancer treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The appendiceal cancer treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The appendiceal cancer treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.
Browse Complete 100  Pages Premium Research Report Enabled with 98 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/appendiceal-cancer-treatment-market-6504
Geographically, the Americas is anticipated to dominate the global appendiceal cancer treatment owing to favorable reimbursement scenario and focus of the government on growing number of rare cancers. According to the American Cancer Society, it affects less than 1000 people each year and accounts for about five percent of all gastrointestinal cancers in the US.
Europe is expected to hold the second largest position in the global appendiceal cancer treatment market. The market growth in this region is attributed to the growing prevalence of cancers and increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cancer cases in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growth initiatives by private healthcare companies.
About US:
Posted by at No comments:

Fibromuscular Dysplasia Market Segmentation Detailed Study with Forecast Up To 2018

Market Scenario:
Fibromuscular dysplasia (FMD) is a disease that causes abnormal cell development in the artery wall, which results in narrowing, i.e., stenosis, and enlargement, i.e., aneurysm of the medium-sized arteries in the body.
According to a study published in the Insights into Imaging in 2015, it is found that the prevalence of fibromuscular dysplasia is estimated to be 4%-6% in the renal arteries and 0.3%-3 % in the cervico-encephalic arteries. Fibromuscular dysplasia is most frequently revealed in the kidneys of young patients associated with resistant hypertension secondary to fibrodysplastic renal artery stenosis. It is also reported that fibromuscular dysplasia is found in around 1% of the hypertensive patients, and is the second leading cause of renovascular hypertension after atherosclerotic disease.
Notably, rising prevalence of fibromuscular dysplasia and increasing R&D expenditure are the key factors driving the fibromuscular dysplasia market. In the year 2016, the R&D expenditure in the pharmaceutical Industry was USD 43,047.9 million, suggested by European Federation of Pharmaceutical Industries and Association.
Various other factors such as increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the global fibromuscular dysplasia market. According to the Eurostat data, it is observed that among the European Union Member States, the highest value of healthcare expenditure was recorded in Germany, i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion, in 2014.
Despite these driving factors, there are some challenges with fibromuscular dysplasia market. Side-effects of treatment, expiration of patented drugs, the presence of misbranded drugs, and poor healthcare system in low and middle-income countries may hamper the growth of the market to a great extent over the review period 2017-2023.
It is estimated that the fibromuscular dysplasia market is expected to grow at a CAGR of 7.5% during the forecast period of 2017-2023.
Segmentation
The global fibromuscular dysplasia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the market is classified as multifocal fibromuscular dysplasia, and focal fibromuscular dysplasia.
On the basis of the diagnosis, the market is classified as physical examination, blood test, catheter-based angiography, doppler ultrasound, computerized tomography (CT) angiogram, magnetic resonance imaging (MRI), and others
On the basis of the treatment, the market is classified as surgery, medication, and others. The surgery segment is further sub-segmented into percutaneous transluminal angioplasty (PTA), and surgical revascularization. The medication segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, calcium channel blockers, and beta blockers.
On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Browse Complete 85  Pages Premium Research Report Enabled with 7 Respective Tables and Figures at https://www.marketresearchfuture.com/reports/fibromuscular-dysplasia-market-5577
Regional Analysis
The Americas dominate the global fibromuscular dysplasia market owing to the rising prevalence of fibromuscular dysplasia and high healthcare expenditure. In 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion, and hospital care accounted for a share of 32.3%, suggested by Centers for Disease Control and Prevention.
Europe holds the second position in the fibromuscular dysplasia market. It is found that the rising research & development expenditure, and amendments in the reimbursement policies in the healthcare are likely to drive the European market.
The Asia Pacific region is the fastest growing fibromuscular dysplasia market owing to the developing healthcare technology, and huge patient pool. Healthcare expenditure of various Asia Pacific countries is also growing steadily. As per the Australian Institute of Health and Welfare in the years 2015-2016, the total healthcare expenditure in Australia was recorded to be USD 170.4 billion, which was around 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.
Key Players
Some of the key players in the global fibromuscular dysplasia market are Alkermes Pharma Ireland Limited, ALVOGEN, Aspen Surgical Products, Inc., AstraZeneca, B. Braun Melsungen AG, Bayer Healthcare Pharmaceuticals Inc., Becton, Dickinson and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd, Ethicon, Inc., Merck, Novartis, Pfizer, Sanofi-Aventis, Smith & Nephew plc; Medtronic, Stryker Corporation, and Watson Pharma Private Limited.
Posted by at No comments:

Tuesday, 23 October 2018

Mucormycosis Market Expected to Grow at High Cagr during Forecast Period 2018 – 2023

Market Scenario:
Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.  
These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.
The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.
The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.
Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the global mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.
The global market for mucormycosis is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.
Research Methodology:

Sources: Annual reports, Press release, White paper, and Company presentation
Intended Audience:
  • Mucormycosis Drug Suppliers
  • Mucormycosis Drug Manufacturers
  • Research and Development (R&D) Companies
  • Medical Research Laboratories
  • Academic Medical Institutes and Universities
Segmentation:
The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.
On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others
On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.
On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.
On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
Regional Analysis:                     
The global mucormycosis market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominate the global mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.
Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.
Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.
While the Middle East & Africa had the lowest share in antifungal treatment market, in 2016.
Key Players:
Some of key the players in the global mucormycosis market are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Comments (Atom)